7 citations
,
July 2019 in “The Journal of Dermatology” This case report describes an 18-year-old male with kerion celsi from Trichophyton tonsurans infection whose condition improved with terbinafine treatment, and highlights that although IL-17A expression increased in skin lesions, it was associated with disrupted antimicrobial peptide expression and severe inflammation, causing tissue damage.
December 2024 in “Kufa Medical journal” The study reported that patients with alopecia areata had significantly higher serum levels of IL-17A and IL-2 compared to healthy controls, suggesting these interleukins may play an important role in the disease, though they did not correlate with its severity or duration.
October 2021 in “Dermatology Reports” This study found that serum IL-17A levels were significantly higher in patients with alopecia areata compared to healthy controls and correlated with disease severity and activity.
September 2021 in “Ukraïnsʹkij žurnal medicini, bìologìï ta sportu” This study found that in patients with alopecia areata, platelet-rich plasma therapy reduced elevated levels of interleukin-17A and interleukin-2 to control levels after 17 months.
20 citations
,
March 2019 in “Case Reports in Dermatology” This report describes two cases where patients developed alopecia while undergoing treatment for psoriasis with IL-17 inhibitors, suggesting an unexpected paradoxical reaction.